Tesamorelin is a growth hormone-releasing hormone analog. It does not directly provide growth hormone. Instead, it signals the pituitary to increase endogenous growth hormone release, which can then influence IGF-1 and downstream metabolic pathways.
Tesamorelin is clinically notable because it is one of the few peptides with a clear approved medical indication. It is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
In a 26-week clinical trial published in the New England Journal of Medicine, daily tesamorelin decreased visceral fat and improved lipid profiles in HIV-infected patients with abdominal fat accumulation.
That distinction is important: tesamorelin is not simply a “weight loss peptide.” Its strongest clinical identity is visceral adipose tissue reduction, especially in a specific medical population. Visceral fat is the fat stored around internal organs. It is metabolically different from subcutaneous fat and is more strongly associated with cardiometabolic risk.
This is why tesamorelin is often discussed in body-composition circles. People interested in abdominal fat reduction tend to focus on the compound because it targets a different axis than GLP-1s. GLP-1s mainly influence appetite and calorie intake. Tesamorelin works through GH-axis signaling.
However, GH-axis compounds need more caution than typical wellness marketing admits. Increasing GH and IGF-1 signaling can affect glucose, fluid retention, joint symptoms, carpal tunnel-like symptoms, and theoretical concerns around active malignancy risk. The Egrifta prescribing information includes warnings and contraindications, including pregnancy and malignancy-related considerations.
The cleanest way to understand tesamorelin:
What it is:
A GHRH analog studied and approved for reducing excess visceral abdominal fat in HIV-associated lipodystrophy.
What it is not:
A casual fat burner, stimulant, or appetite suppressant.
Why people discuss it:
It targets visceral fat through a pathway different from GLP-1s.
What to be careful with:
GH/IGF-1 effects, glucose changes, water retention, and medical screening.
For research and educational content, tesamorelin should be framed as a clinical peptide with specific evidence, not as a general-purpose shortcut. Its value is in precision: visceral fat, GH-axis signaling, and body-composition research.